IRLA Quince Therapeutics, Inc.: institutional ownership and insider trading
28 funds reported holding $22.6M of Quince Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $11.3M, with 28 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $174K on the open market.
IRLA revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$75.5M, EPS -12.31
- Quarter ended Mar 31, 2026: revenue n/a, net income $35.9M, EPS 2.88
- Quarter ended Dec 31, 2025: revenue n/a, net income −$39.5M, EPS 70.74
- Quarter ended Sep 30, 2025: revenue n/a, net income −$13.4M, EPS -0.25
Famous investors holding IRLA
- Izzy Englander (Millennium Management): $1.29M, 0.0% of the portfolio
Largest institutional holders of IRLA
- BALYASNY ASSET MANAGEMENT L.P. — $12.6M
- TUDOR INVESTMENT CORP ET AL — $4.25M
- Ikarian Capital, LLC — $1.31M
- MILLENNIUM MANAGEMENT LLC — $1.29M
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $1.00M
- Squadron Capital Management LLC — $734K
- Shay Capital LLC — $329K
- BOOTHBAY FUND MANAGEMENT, LLC — $253K
- JANE STREET GROUP, LLC — $230K
- VANGUARD CAPITAL MANAGEMENT LLC — $219K
Recent IRLA insider trades
- Dec 26, 2025: Benatti Luca sold 50,000 shares ($174K)
5%+ owners
- BALYASNY ASSET MANAGEMENT L.P.: 10.0% (Schedule 13G, filed Aug 14, 2026)
- Cormorant Asset Management, LP: 10.0% (Schedule 13G, filed Aug 14, 2026)
- Ikarian Capital, LLC: 9.0% (Schedule 13G, filed Aug 14, 2026)
- Perceptive Advisors LLC: 8.4% (Schedule 13G, filed Oct 14, 2026)
- James B. Tananbaum: 6.0% (Schedule 13G, filed Oct 14, 2026)
- Squadron Master Fund LP: 5.6% (Schedule 13G, filed Aug 4, 2026)